Immunological consequences of ionising radiation in combination with ADT-414 in human glioblastoma

"Our studies will impact the understanding of the causation of pseudoprogression-type therapeutic responses in human glioblastoma multiforme(GBM) and the treatments used for brain cancer. Here we will confirm in cutting-edge preclinical models the likely immunogenic properties of a promising new brain cancer drug therapy, ABT-414 and its novel likely interaction with an established immunomodulatory brain cancer therapy, ionising radiation (IR)."

- Prof Michael McKay, Olivia Newton-John Cancer Research Institute